colon cancer
FDA gives Bayer’s colon cancer drug “priority”
- Thu, 06/28/2012 - 2:29pm
The U.S. Food and Drug Administration accepted Bayer’s experimental drug regorafenib for priority review, which could make it marketable in a matter of six months.
-
Warfarin alternatives create concerns
- Jun 22, 2012
-
Judge consolidates Wright Conserve hip replacements into MDL
- Mar 16, 2012
-
FDA advisory committee ordered to conduct new Yaz and Yasmin meeting
- Jan 18, 2012
-
Man alleges Actos caused bladder cancer in four months’ time
- Jun 19, 2012
-
Increased blood clot risk associated with newer birth controls
- Jan 5, 2012
-
Johnson & Johnson sued for vaginal mesh complications
- Feb 15, 2012
-
FDA issues warning after codeine kills children post-surgery
- Aug 16, 2012
-
Artificial retina gives sight to blind mice
- Aug 16, 2012
-
Lucentis approved for diabetic macular edema
- Aug 14, 2012
-
Mayo Clinic: Patients in the dark about prescriptions
- Aug 9, 2012
-
Hospital's plan to prevent painkiller abuse
- Aug 8, 2012
-
Alzheimer's drug disappoints
- Aug 8, 2012
listeria bladder cancer Products Avandia type 2 diabetes blindness Pradaxa pulmonary embolism stroke testing Tempah Adderall Medicaid Perjeta Travel Fosamax Nesina Fen-Phen coumadin kidney problems femur fractures blood clots blood thinners SSRI meningitis FDA venous thromboembolism MenHibrix D.C. breast cancer
More Dangerous Drug News
Get News Updates By Email
@ConsumerDrugRep Tweets
Archives
- June 2011 (3)
- September 2011 (1)
- October 2011 (3)
- November 2011 (5)
- December 2011 (25)
- January 2012 (8)
- February 2012 (24)
- March 2012 (20)
- April 2012 (6)
- May 2012 (12)